Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study

• Published in: Immunology letters Vol. 248; pp. 70 - 77
• Main Authors: Cavaliere, Carlo, Segatto, Marco, Ciofalo, Andrea, Colizza, Andrea, Minni, Antonio, Messineo, Daniela, Lambiase, Alessandro, Greco, Antonio, de Vincentiis, Marco, Masieri, Simonetta
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.08.2022
• Subjects: Benralizumab; CRSwNP; Eosinophils; Severe asthma; Benralizumab; CRSwNP; Severe asthma; Eosinophils
• ISSN: 0165-2478; 1879-0542; 1879-0542
• DOI: 10.1016/j.imlet.2022.06.009

•Bernalizumab improves asthma control, confirming the literature and clinical practice.•In our study Benralizumab would seem to improve rhinosinusitis symptoms in real life.•Anti IL-5R appears to modulate Type 2 and non-Type 2 inflammation markers.•Our study shows a significant reduction of NPS and radiological score in severe asthma and CRSwNP. Chronic rhinosinusitis with nasal polyps (CRSwNP) and Severe Eosinophilic Asthma (SEA) are both frequently sustained by eosinophilic inflammation and are probably the manifestation of a unique disease of upper and lower respiratory tract. We retrospectively observed 11 patients with severe CRSwNP and concomitant SEA under add-on therapy with benralizumab evaluating symptoms using Sino Nasal Outcome Test-22 (SNOT-22), Visual Analogue Scale (VAS), and Asthma Control Test (ACT) and Nasal polyp size by endoscopic and radiological score by Nasal Polyp Score (NPS) and Lund-Mackay Score (LMS). At 6 and 12 months, the expression of cationic eosinophil protein (ECP), Interleukin 17 (IL-17), Interferon gamma (INF-γ), and vascular endothelial growth factor (VEGF) was measured by nasal scraping to assess mucosal inflammation. After 12 months of benralizumab treatment, SNOT-22 decreased from 45 (23–97) to 14 (5–53) (p < 0.05), total VAS of rhinologic symptoms decreased from 30 (17–44) to 9 (5–37) (p ≤ 0.01) and ACT score increased from 10 (5–15) to 24 (20–25) (p ≤ 0.01). NPS decreased from 5 (3–6) to 3 (2–4) after 6 months (p < 0.05) and to 2 (2–3) after one year respectively (p <  0.05) and LMS total score from 21 (15–24) to 17 (8–21) (p ≤ 0.01) after 12 months from starting treatment. Nasal mucosa scraping found differences in INF-γ and VEGF expression in patients compared to 10 healthy subjects, with a normalization of these markers during eosinophils depletion induced by benralizumab. This is the first pilot real-life study conducted with an anti-IL5R monoclonal antibody in severe eosinophilic asthma and severe CRSwNP patients showing that this treatment can induce benefit both diseases not only from the clinical, but also from the inflammatory point of view. Moreover, our research pointed out that INF-γ and VEGF may represent potential response biomarker.